Population pharmacokinetic/pharmacodynamic assessment of imipenem/cilastatin/relebactam in patients with hospital‐acquired/ventilator‐associated bacterial pneumonia

• Main Authors: Munjal Patel (Author), Francesco Bellanti (Author), Naveen M. Daryani (Author), Nadia Noormohamed (Author), David W. Hilbert (Author), Katherine Young (Author), Pooja Kulkarni (Author), William Copalu (Author), Ferdous Gheyas (Author), Matthew L. Rizk (Author)
• Format: Book
• Published: Wiley, 2022-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract In the phase III RESTORE‐IMI 2 study (ClinicalTrials.gov: NCT02493764), the combination antibacterial agent imipenem/cilastatin/relebactam (IMI/REL) demonstrated noninferiority to piperacillin/tazobactam for the end points of all‐cause mortality at day 28 and favorable clinical response at...